{"paper_id":"603bc69e-88d8-4bbc-8929-627b51dbfc6b","body_text":"Abstract\nPurpose\nThe purpose of this study was to examine the effects of atorvastatin in the treatment of experimental endometriosis.\nMethods\nEndometriosis was induced in 24 female rats. 4 weeks after the procedure dimensions of the foci were recorded. Rats were divided into three groups: in Group 1 (n = 8), a daily dose of 10 mg/kg atorvastatin was given for 14 days. In the second group (n = 8), a single dose of 1 mg/kg leuprolide acetate was injected intraperitoneally. The rats in Group 3 (n = 8) were received 1 mg/kg i.p. 0.9 % NaCl. At the end of the treatment, laparotomy was performed, and the dimensions of the endometriotic foci were recorded. Biochemical, histopathological and immunohistochemical studies were performed and nociception was compared in groups.\nResults\nAtorvastatin treatment exhibited significant analgesic activity in hot plate model (P = 0.022). The serum hs-CRP and tumor necrosis TNF-α levels were similar between the Group 2 and Group 3 (P > 0.05); however atorvastatin caused significant decrease in both serum markers. The histological and immunohistochemical scores were also found to be markedly lower in Group 1 and Group 2 (P < 0.05).\nConclusion\nAtorvastatin treatment may have a therapeutic potential in the treatment of endometriosis through its anti-inflammatory and anti-nociceptive properties.\nSimilar content being viewed by others\nReferences\nVignali M, Infantino M, Matrone R, Chiodo I, Somigliana E, Busacca M, Viganò P (2002) Endometriosis: novel etiopathogenetic concepts and clinical perspectives. Fertil Steril 78(4):665–678\nGiudice LC, Kao LC (2004) Endometriosis. Lancet 364(9447):1789–1799\nMatarese G, De Placido G, Nikas Y, Alviggi C (2003) Pathogenesis of endometriosis: natural immunity dysfunction or autoimmune disease? Trends Mol Med 9(5):223–228\nOlivares C, Bilotas M, Buquet R, Borghi M, Sueldo C, Tesone M, Meresman G (2008) Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis. Hum Reprod 23(12):2701–2708. doi:10.1093/humrep/den315\nCelik O, Hascalik S, Elter K, Tagluk ME, Gurates B, Aydin NE (2008) Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways. Hum Reprod 23(11):2458–2465. doi:10.1093/humrep/den246\nAgic A, Xu H, Finas D, Banz C, Diedrich K, Hornung D (2006) Is endometriosis associated with systemic subclinical inflammation? Gynecol Obstet Invest 62(3):139–147\nKappou D, Matalliotakis M, Matalliotakis I (2010) Medical treatments for endometriosis. Minerva Ginecol 62(5):415–432\nJacobson TZ (2011) Potential cures for endometriosis. Ann N Y Acad Sci 1221:70–74. doi:10.1111/j.1749-6632.2010.05933.x\nWang F, He YL, Peng DX, Liu MB (2005) Expressions of nuclear factor-kappaB and intercellular adhesion molecule-1 in endometriosis. Di Yi Jun Yi Da Xue Xue Bao 25:703–705\nClearfield M, Whitney EJ, Weis S, Downs JR, Shapiro DR, Stein EA, Watson DJ, Langendörfer A, Beere PA, Stamler J, Gotto AM Jr (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615–1622\nGhaisas MM, Dandawate PR, Zawar SA, Ahire YS, Gandhi SP (2010) Antioxidant, antinociceptive and anti-inflammatory activities of atorvastatin and rosuvastatin in various experimental models. Inflammopharmacology 18(4):169–177. doi:10.1007/s10787-010-0044-6\nTaubes G (2002) Does inflammation cut to the heart of the matter? Science 296:242–245\nSchönbeck U, Libby P (2004) Inflammation, immunity, and HMGCoA reductase inhibitors: statins as antiinflammatory agents? Circulation 109:8–26\nGrip O, Janciauskiene S, Bredberg A (2008) Use of atorvastatin as an anti-inflammatory treatment in Crohn’s disease. Br J Pharmacol 155:1085–1092. doi:10.1038/bjp.2008.369\nHogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagne C, Couture P (2008) Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism 57:380–386. doi:10.1016/j.metabol.2007.10.014\nGross GH (1977) A technique for sustained synchronization of hamster estrous cycles by hormonal means. Horm Behav 9:23–31\nVernon MW, Wilson EA (1985) Studies on the surgical induction of endometriosis in the rat. Fertil Steril 44:684–694\nBirnbaum Y, Lin Y, Ye Y, Merla R, Perez-Polo JR, Uretsky BF (2008) Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat. J Cardiovasc Pharmacol Ther 13(1):72–79. doi:10.1177/1074248407312839\nDogan E, Saygili U, Posaci C, Tuna B, Caliskan S, Altunyurt S, Saatli B (2004) Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib. Fertil Steril 82(Suppl 3):1115–1120\nPorreca F, Mosberg HI, Hurst R, Hruby VJ, Burks TF (1984) Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther 230(2):341–348\nForster MJ, Lal H (1999) Estimating age-related changes in psychomotor function: influence of practice and of level of caloric intake in different genotypes. Neurobiol Aging 20(2):167–176\nYucel A, Aydogan MS, Parlakpinar H, Erdogan MA, Kurt A, Ucar M, Durmus M (2012) Effects of propofol and dexmedetomidine on motor coordination and analgesia: a comparative analysis. Int J Clin Pharmacol Ther 50(9):678–682. doi:10.5414/CP201696\nSimsek Y, Celik O, Karaer A, Gul M, Yılmaz E, Koc O, Colak C, Zengin S, Aydin NE (2012) Therapeutic efficiency of Atosiban, an oxytocin receptor blocking agent in the treatment of experimental endometriosis. Arch Gynecol Obstet 286(3):777–783. doi:10.1007/s00404-012-2390-7\nKianpour M, Nematbakhsh M, Ahmadi SM (2012) C-reactive protein of serum and peritoneal fluid in endometriosis. Iran J Nurs Midwifery Res 17(2 Suppl 1):S115–S119\nLermann J, Mueller A, Körber F, Oppelt P, Beckmann MW, Dittrich R, Renner SP (2010) Evaluation of high-sensitivity C-reactive protein in comparison with C-reactive protein as biochemical serum markers in women with endometriosis. Fertil Steril. 93(7):21–2129. doi:10.1016/j.fertnstert.2009.01.072\nXavier P, Belo L, Beires J, Rebelo I, Martinez-de-Oliveira J, Lunet N, Barros H (2006) Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis. Arch Gynecol Obstet 273(4):227–231\nJialal I, Devaraj S, Venugopal SK (2004) C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 44:6–11\nScholl B, Bersinger NA, Kuhn A, Mueller MD (2009) Correlation between symptoms of pain and peritoneal fluid inflammatory cytokine concentrations in endometriosis. Gynecol Endocrinol 25(11):701–706. doi:10.3109/09513590903159680\nLee GH, Choi YM, Kim SH, Hong MA, Oh ST, Lim YT, Moon SY (2008) Association of tumor necrosis factor-{alpha} gene polymorphisms with advanced stage endometriosis. Hum Reprod 23(4):977–981. doi:10.1093/humrep/den016\nEisermann J, Gast MJ, Pineda J, Odem RR, Collins JL (1988) Tumor necrosis factor in peritoneal fluid of women undergoing laparoscopic surgery. Fertil Steril 50(4):573–579\nIwabe T, Harada T, Terakawa N (2002) Role of cytokines in endometriosis-associated infertility. Gynecol Obstet Invest 53(Suppl 1):19–25\nOktem M, Esinler I, Eroglu D, Haberal N, Bayraktar N, Zeyneloglu HB (2007) High-dose atorvastatin causes regression of endometriotic implants: a rat model. Hum Reprod 22(5):1474–1480\nRodriguez AL, Wojcik BM, Wrobleski SK, Myers DD Jr, Wakefield TW, Diaz JA (2012) Statins, inflammation and deep vein thrombosis: a systematic review. J Thromb Thrombolysis 33(4):371–382. doi:10.1007/s11239-012-0687-9\nGarcia GG, Miranda HF, Noriega V, Sierralta F, Olavarría L, Zepeda RJ, Prieto J (2011) Antinociception induced by atorvastatin in different pain models. Pharmacol Biochem Behav 100(1):125–129. doi:10.1016/j.pbb.2011.08.007\nSantodomingo-Garzón T, Cunha TM, Verri WA Jr, Valério DA, Parada CA, Poole S, Ferreira SH, Cunha FQ (2006) Atorvastatin inhibits inflammatory hypernociception. Br J Pharmacol 149(1):14–22\nConflict of interest\nNone.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nSimsek, Y., Gul, M., Yilmaz, E. et al. Atorvastatin exerts anti-nociceptive activity and decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in a rat endometriosis model. Arch Gynecol Obstet 290, 999–1006 (2014). https://doi.org/10.1007/s00404-014-3295-4\nReceived:\nAccepted:\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s00404-014-3295-4","source_license":"CC0","license_restricted":false}